Nurix Therapeutics gets $700M upfront in a potential $2.3B partnership with Roche to co-develop bexobrutideg, a next-gen oral BTK degrader for CLL, MS, and immunology.
Morgan Stanley updates biotech views, downgrading Arcus and IO Biotech while upgrading Nurix on stronger pipeline prospects.
Nurix Therapeutics presented positive Phase 1 data for its BTK degrader, bexobrutideg (NX-5948), showing high response rates and favorable safety in heavily pre-treated Waldenström Macroglobulinemia patients.
